Disclosure: I’m participating in the Break Up with Your Makeup Blogger Contest
Sponsored by Galderma Laboratories, L.P.
The appearance of my skin is very important to me, and I try to make it look as fresh as possible. I’m lucky to have never experienced symptoms of rosacea, but many of my close friends have. Rosacea is a treatable, chronic inflammatory skin condition and one of the most common symptoms is persistent facial redness. It’s estimated that 16MM Americans are affected by the condition. Unfortunately, not many people know it is treatable and instead cake on the makeup to conceal the redness. That’s why I’m excited that Mirvaso, the only FDA-approved treatment for the persistent redness of rosacea, is hosting this sweepstakes to raise awarenessof the treatment, encouraging people to Break Up with Your Makeup. Mirvaso works fast, providing same-day results that last up to 12 hours before theredness returns, leaving users red-carpet ready!
You can check out more information, and enter to win a trip to the Emmys in Los Angeles here:
Important Safety Information
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Posts
